Jun Sheng Tai Pharmaceuticals-B (02511) plummeted more than 60% during yesterday's trading session, and opened high by nearly 6% in early trading today. As of the time of publication, it has risen by 5.92%, to HKD 1.61, with a turnover of HKD 2.8811 million.
According to the Wisdom Financial App, Jun Sheng Tai Pharmaceuticals-B (02511) plummeted more than 60% during yesterday's trading session, and opened high by nearly 6% in early trading today. As of the time of publication, it has risen by 5.92%, to HKD 1.61, with a turnover of HKD 2.8811 million.
On the news front, Jun Sheng Tai Pharmaceuticals issued a statement regarding the unusual stock price fluctuations, confirming that following a reasonable investigation, they are not aware of any reasons for recent fluctuations in the stock price. They also confirmed that the Group's business operations remain normal and that there have been no significant adverse changes in its business operations or financial condition.
It is reported that Jun Sheng Tai Pharmaceuticals has not yet achieved product commercialization, and the company's main business revenue has been zero. Analysts point out that the uncertainty of B-class pharmaceutical companies listed on the Hong Kong stock market is relatively high for future development. When the risk appetite of market funds decreases, these stocks may be sold off. In addition, Jun Sheng Tai Pharmaceuticals has only been listed for six months, and the lock-up period of the first phase has arrived, which to some extent has increased the ask volume.